Artemether (RIAMET 20 mg/120 mg artemether/lumefantrine 20 mg/120 mg dispersible tablet blister pack)
Artemether risk profile, scheduling, and guidance for claims professionals and care workers . Also known as RIAMET 20 mg/120 mg artemether/lumefantrine 20 mg/120 mg dispersible tablet blister pack, COARTEM 20 mg /120 mg artemether/lumefantrine 20 mg/120 mg dispersible tablet blister pack.
Artemether (brand names: RIAMET 20 mg/120 mg artemether/lumefantrine 20 mg/120 mg dispersible tablet blister pack, COARTEM 20 mg /120 mg artemether/lumefantrine 20 mg/120 mg dispersible tablet blister pack) is classified as Low risk (1 risk points) by AllMeds. It is a S4 medication under the TGA in Australia. Antimalarial with mild QTc risk but short-term use for specific indication.
Key Takeaways
- TGA Schedule: S4 in Australia
- Risk level: Low (1 points)
- Recommended maximum duration: 3 days
Scheduling and Classification
| Jurisdiction | Classification | Status |
|---|---|---|
| Australia (TGA) | S4 | Not PBS listed |
Risk Profile
Antimalarial with mild QTc risk but short-term use for specific indication.
Regulatory and Compliance Guidance
When Artemether appears on a claimant's medication list, claims professionals should assess whether the prescribing is appropriate for the compensable injury, whether the duration is within guidelines, and whether there are interactions with other medications on the claim.
Australia TGA / PBS / State Schemes
Classified as S4 under the Therapeutic Goods Administration (TGA).
Need to assess this medication across your caseload?
Run a full risk assessment including Artemether interactions and compliance checks.
AllMeds gives you instant risk assessments, compliance checks, and automated letters for every medication on a claim.
No credit card required. No signup for your first 2 questions.
Medical Disclaimer: This content is for informational purposes for claims professionals and care workers. It is not medical advice. Always consult a qualified healthcare professional for clinical decisions. Drug information is sourced from TGA, FDA, MHRA, PBS, NICE, and CDC databases and may not reflect the latest updates. AllMeds does not replace clinical judgement.